Background Chimeric antigen receptor-modifed T cells (CAR T-cells) have shown exhilarative clinical efcacy for hematological malignancies. However, a shared antigen pool between healthy and malignant T-cells remains a concept to be technically and clinically explored for CAR T-cell therapy in T-cell cancers. No guidelines for engineering CAR T-cells targeting self-expressed antigens are currently available. Method Based on anti-CD70 CAR (CAR-70) T-cells, we constructed CD70 knock-out and wild-type CAR (CAR-70KO and CAR-70WT) T-cells and evaluated their manufacturing and anti-tumor capability. Single-cell RNA sequencing and TCR sequencing were performed to further reveal the underlying diferences between the two groups of CAR T-cells. Results Our data showed that the disruption of target genes in T-cells before CAR transduction advantaged the expansion and cell viability of CAR T-cells during manufacturing periods, as well as the degranulation, anti-tumor efcacy, and proliferation potency in response to tumor cells. Meanwhile, more naïve and central memory phenotype CAR+ T-cells, with higher TCR clonal diversity, remained in the fnal products in KO samples. Gene expression profles revealed a higher activation and exhaustion level of CAR-70WT T-cells, while signaling transduction pathway analysis identifed a higher level of the phosphorylation-related pathway in CAR-70KO T-cells. Conclusion This study evidenced that CD70 stimulation during manufacturing process induced early exhaustion of CAR- 70 T-cells. Knocking-out CD70 in T-cells prevented the exhaustion and led to a better-quality CAR-70 T-cell product. Our research will contribute to good engineering CAR T-cells targeting self-expressed antigens.